期刊
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL
卷 9, 期 3-4, 页码 90-96出版社
CANADIAN UROLOGICAL ASSOCIATION
DOI: 10.5489/cuaj.2526
关键词
-
资金
- Amgen
- Astellas
- Janssen
- Abbott
- Sanofi
- Bayer
- OncoGenex Technologies Inc.
- Novartis
- Pfizer
- GSK
- GE Healthcare
- Best Medical and Varian Medical Systems
Agents that have shown improvements in survival in mCRPC now include abiraterone, enzalutamide, docetaxel, cabazitaxel and radium-223. Bone supportive agents and palliative radiation continue to play an important role in the overall management of mCRPC. Given the complexity, variety and importance of optimizing the use of these agents, a multidisciplinary team approach is highly recommended.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
